| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/17/2004 | US20040116329 Administering to at least one cell in a blood vessel wall after an angioplastic procedure an amount of a compound capable of inhibiting the ubiquitin-proteasome protein degradation pathway in cell effective to prevent proliferation of cell |
| 06/17/2004 | US20040115775 Homogeneity and secretion of recombinant proteins in mammalian systems |
| 06/17/2004 | US20040115773 Serpin in bifidobacteria |
| 06/17/2004 | US20040115770 Preparing genetically engineered cystic fibrosis trans-membrane conductance regulator protein with enhanced activty for treatment of respiratory disorders |
| 06/17/2004 | US20040115769 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 06/17/2004 | US20040115766 Using thermophilic microorganisms as bioreactors for generating polypeptides for use treament of skin disorders; antitumor agens; antiaging agents |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115747 Using expression vector coding tumor supressor protein to identify compounds which induce cell death; diagnosing xeroderma pigmentosum |
| 06/17/2004 | US20040115738 Polypeptides having a triggering nk activity and biological applications |
| 06/17/2004 | US20040115714 Comprises nucleotide coding sequences associated with breast cancer cell-2 (BRCC-2) genes and proteins for use in the identification of modulators for prevention and treatment of tumors |
| 06/17/2004 | US20040115698 Interleukin 17 receptor-like protein |
| 06/17/2004 | US20040115690 Method of detecting inflammatory lung disorders |
| 06/17/2004 | US20040115687 Comprise matrix polypeptide for diagnosis, treatment, and prevention of immunological, nervous system, developmental, connective tissue and cell proliferative disorders |
| 06/17/2004 | US20040115670 Identifying modulators of exopeptidase for use in diagnosis, prevention and treatment of asthma and cancer |
| 06/17/2004 | US20040115667 Dna-sequences, which code for an apoptosis signal transduction protein |
| 06/17/2004 | US20040115651 Modulation of BUB3 expression |
| 06/17/2004 | US20040115650 Modulation of MAD1-like 1 expression |
| 06/17/2004 | US20040115649 Modulation of ABCC5 expression |
| 06/17/2004 | US20040115645 Modulation of DRAK2 expression |
| 06/17/2004 | US20040115640 Modulation of angiopoietin-2 expression |
| 06/17/2004 | US20040115638 Modulation of tumor susceptibility gene 101 expression |
| 06/17/2004 | US20040115635 Modulation of PTPN13 expression |
| 06/17/2004 | US20040115633 Modulation of mitochondrial ribosome protein S16 expression |
| 06/17/2004 | US20040115631 Nucleic acid coding for a bonding site of a protein kinase of the mitogenic signalling cascade of a clycolysis-catalysing enzyme |
| 06/17/2004 | US20040115629 Molecules for diagnostics and therapeutics |
| 06/17/2004 | US20040115587 Methods and systems for enabling and stabilizing tooth movement |
| 06/17/2004 | US20040115483 Crystal modification of a cyclic depsipeptide having improved strength |
| 06/17/2004 | US20040115287 Hydrophobic active agent compositions and methods |
| 06/17/2004 | US20040115285 Orally administering a proanthocyanidins containing plant extract to hyperglycemic patient to lower elevated level of blood glucose or glycosylated hemoglobin levels |
| 06/17/2004 | US20040115284 Use of gamma-GT inhibitors for the treatment of degenerative diseases |
| 06/17/2004 | US20040115283 Administering parenterally a therapeutically effective amount of one or more arsenic compounds |
| 06/17/2004 | US20040115281 Microparticles |
| 06/17/2004 | US20040115227 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 06/17/2004 | US20040115222 Method for reduction of wrinkles |
| 06/17/2004 | US20040115217 Bystander suppression of autoimmune diseases |
| 06/17/2004 | US20040115211 fusions between ESAT-6 and MPT59 are superior immunogens |
| 06/17/2004 | US20040115208 forming a colloidal metal-protein complex by contacting colloidal metal with a tumor cell in an aqueous solution |
| 06/17/2004 | US20040115206 by contacting with an anti-L1CAM antibody or L1CAM-binding fragment thereof to inhibit cell growth or induce cell death |
| 06/17/2004 | US20040115200 administering to cerebrospinal fluid anti-TNF antibodies, fragments and regions thereof that are specific for human tumor necrosis factor- alpha |
| 06/17/2004 | US20040115199 Method for down-regulating osteoprotegerin ligand activity |
| 06/17/2004 | US20040115195 treating bone disorders resulting in increased trabecular bone formation, decreased osteoblast and osteocyte apoptosis and increased osteoprogenitor differentiation |
| 06/17/2004 | US20040115191 Method for treating psoriasis |
| 06/17/2004 | US20040115190 Methods and agents modulating upa/upar activity |
| 06/17/2004 | US20040115189 especially injectable and spray pharmaceutical formulations. |
| 06/17/2004 | US20040115188 Enzyme with proteolytic activity |
| 06/17/2004 | US20040115186 a urease enzyme, and having associated with it a chemical entity effective to enhance the delivery of the enzyme to cancer cells |
| 06/17/2004 | US20040115185 Placental alkaline phosphatase to control diabetes |
| 06/17/2004 | US20040115184 Methods and compositions for modifying apolipoprotein b mrna editing |
| 06/17/2004 | US20040115183 Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-senstive diseases |
| 06/17/2004 | US20040115182 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
| 06/17/2004 | US20040115175 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 06/17/2004 | US20040115170 reducing viability of a tumor cell by administering a non-naturally occuring reovirus expressing a particular mu-2 protein or a virus capable of expressing the reovirus mu-2 protein |
| 06/17/2004 | US20040115169 Methods of protein purification and recovery |
| 06/17/2004 | US20040115166 Method of treatment and prophylaxis |
| 06/17/2004 | US20040115139 Botulinum toxin dental therapies and procedures |
| 06/17/2004 | US20040115135 Bioavailability; side effect reduction |
| 06/17/2004 | US20040115128 Targeting endothelium for tissue-specific delivery of agents |
| 06/17/2004 | US20040112376 Method of inducing euglycemia in diabetic patients |
| 06/17/2004 | DE10255861A1 Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase |
| 06/17/2004 | CA2509955A1 Formulations useful against hepatitis c virus infections |
| 06/17/2004 | CA2508765A1 Bone growth factor |
| 06/17/2004 | CA2508514A1 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 06/17/2004 | CA2508052A1 Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| 06/17/2004 | CA2507990A1 Novel ifngamma-like polypeptides |
| 06/17/2004 | CA2507863A1 Methods and materials for modulating trpm2 |
| 06/17/2004 | CA2507711A1 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 06/17/2004 | CA2507709A1 Therapeutic and diagnostic agents |
| 06/17/2004 | CA2507668A1 Methods of treating cerebral ischemia |
| 06/17/2004 | CA2507626A1 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
| 06/17/2004 | CA2507450A1 Use of a histone deacetylase inhibitor for treating muscular dystrophies |
| 06/17/2004 | CA2507051A1 Treatment of diseases and conditions mediated by increased phosphorylation |
| 06/17/2004 | CA2507036A1 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | CA2507011A1 Phosphoantigens for regulating an immune response |
| 06/17/2004 | CA2505150A1 Aza-peptides |
| 06/17/2004 | CA2503973A1 Material compositions and related systems and methods for treating cardiac conditions |
| 06/17/2004 | CA2503346A1 Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2481489A1 Cysteine protease inhibitor |
| 06/17/2004 | CA2469724A1 Mutant glycoproteins |
| 06/17/2004 | CA2453387A1 Compositions and methods related to nitrotyrosine-containing compounds as antigenic agents |
| 06/16/2004 | EP1428891A1 Novel gene nedl-1 |
| 06/16/2004 | EP1428887A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 06/16/2004 | EP1428883A1 Megakaryocyte stimulating factors |
| 06/16/2004 | EP1428881A1 Hematopoietic stem cell proliferation regulators and polynucleotides encoding the same |
| 06/16/2004 | EP1428880A1 Kidney-specific urate transporter and gene thereof |
| 06/16/2004 | EP1428879A1 Polynucleotide vaccine |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428834A1 Ligands for flt3 receptors |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1428530A1 Tetrapeptide derivative crystals |
| 06/16/2004 | EP1428524A1 Pulmonary delivery of aerosolized medicaments |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427855A2 Method and reagents for identifying gene targets for treating breast cancer |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427831A1 Yeast membrane protein expression system and its application in drug screening |
| 06/16/2004 | EP1427830A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 06/16/2004 | EP1427829A2 Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| 06/16/2004 | EP1427827A2 Synthetic hcv envelope proteins and their use for vaccination |
| 06/16/2004 | EP1427824A2 Use of microbiology non-viral substances for treating acne |
| 06/16/2004 | EP1427820A2 Modified factor ix |